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Abstract
Mutations in one of the five genes encoding the succinate dehydrogenase (SDHx) or mitochondrial complex II 
cause the corresponding family syndromes characterized by the occurrence of pheochromocytomas (PHEO) and 
paragangliomas (PGL). Recently, other solid growths, such as gastrointestinal stromal tumors (GISTs), renal cell 
carcinomas (RCCs) and pituitary adenomas (PAs) have been associated with these syndromes. In the absence of 
prospective studies assessing their frequency, at present, their occurrence seems too infrequent to suggest systematic 
screening for SDHx mutation carriers. However, SDHB immunohistochemistry (IHC) on tumor tissues or SDHx 
genetic testing on blood or tumor samples should be performed in patients affected by GISTs, RCCs or PAs with 
clinicopathologic phenotypes suggesting an etiologic role of SDHx genes.
Introduction
Pheochromocytomas (PHEO) and paragangliomas (PGL) 
are rare neural crest-derived tumors (1, 2). They comprise 
adrenal and extra-adrenal chromaffin, sympathetic, 
catecholamine releasing tumors, namely secreting PGL 
(sPGL) and tumors of the parasympathetic ganglia in 
the head and neck region, namely head and neck PGL 
(HNPGL). These tumors are the most common heritable 
tumors recorded to date (3, 4). Approximately 35% of 
them are caused by germline mutations and an additional 
10–15% show somatic mutations in the same or other 
susceptibility genes, which include those encoding 
the succinate dehydrogenase (SDH) or mitochondrial 
complex II (5).
SDH is functionally involved in both the Krebs cycle, 
where it transforms succinate into fumarate, and the 
electron transport chain. The complex consists of four 
structural subunits: two hydrophilic catalytic subunits, 
A and B, encoded by the corresponding SDHA and SDHB 
genes and two hydrophobic subunits, C and D, encoded 
by SDHC and SDHD genes anchoring the catalytic 
subunits to the inner mitochondrial membrane (6). 
Enzymatic activity requires a functional unit, succinate 
dehydrogenase complex assembly factor 2 (SDHAF2), 
responsible for flavination of the catalytic subunit A and 
encoded by the corresponding SDHAF2 gene (7).
Mutations in any of these five genes cause disassembly 
of the mitochondrial complex, with loss of SDH 
enzymatic activity (8, 9) as well as of SDHB expression at 
immunohistochemistry (IHC) while SDHA is lost, together 
with SDHB, in SDHA-mutated tumors, but its expression 
is retained in tumors with other SDH mutations.
Consequently, SDHB IHC (10) has been assumed as a 
rapid and inexpensive preliminary test on tumor tissue to 
investigate on tumor’s SDH insufficiency.
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Mutations in any of these five genes cause impairment 
of SDH enzymatic activity and loss of SDHB expression, 
whereas loss of SDHA expression is only detected in SDHA 
mutations (8, 9). SDH immunohistochemistry (IHC) has 
therefore become a rapid and inexpensive tool for testing 
SDH insufficiency in tumor tissue (10).
Mutations in any of the five SDH genes are responsible 
for the occurrence of PHEO/PGL.
In 2000, Baysal et  al. (5) demonstrated that SDHD 
mutations result in an inherited familial syndrome, 
known as familial paragangliomatosis type 1 (PGL1) 
characterized by the presence of both sPGL and HNPGL 
(11). Subsequently, other SDHx genes also proved to be 
PHEO/PGL susceptibility genes (12, 13, 14, 15), and their 
germline mutations are associated with the corresponding 
familial syndromes, namely PGL2 to PGL5 (Table 1). The 
clinical picture of these five PGL syndromes differs in some 
aspects, but they are all characterized by the presence of 
PHEO/PGL (16, 17, 18, 19, 20).
In recent years, germline mutations in SDHx genes 
have been rarely associated with other solid tumors 
beyond PHEO/PGL, such as gastrointestinal stromal 
tumors (GISTs) (21), renal cell carcinomas (RCC) (22) 
and pituitary adenomas (PAs) (23). To our knowledge, no 
systematic prospective study has been conducted in SDHx 
mutation carriers to define the true prevalence of solid 
tumors other than PHEO/PGL. These additional solid 
tumors have been sometimes found incidentally in SDHx 
mutation carriers and most of the papers evaluating the 
role of SDH in the pathogenesis of these tumors report 
retrospective studies performed by SDHB IHC on paraffin-
embedded tumor tissue. Tumors have been labeled as ‘SDH 
deficient’ in case of negative SDHB immunostaining but 
not all the tumors or the patients have then undergone 
genetic analysis looking for the correspondent SDHx 
somatic or germline mutations.
This paper reviews these tumors and their 
characteristics.
Gastrointestinal stromal tumors (GISTs)
GISTs are the most common mesenchymal tumors of the 
gastrointestinal tract (24), occurring as sporadic or familial 
with an incidence of 6.8–20 per million (25, 26, 27).
In 85–90% of cases, GISTs result from activating 
mutations of KIT or PDGFRA genes (28, 29). The other 
10–15% non-KIT/PDGFRA-mutated GISTs, incorrectly 
labeled as ‘wild type’, mainly affect children. Mutations 
in NF1 (30, 31) or BRAF (32) genes account for 50% of 
these cases, while the remaining 50% prove negative 
for SDHB on IHC, and are referred to as SDH-deficient 
GISTs. They can be sporadic or part of two syndromes, 
i.e. Carney-Stratakis (33) syndrome and Carney triad (34). 
In Carney-Stratakis syndrome, dominantly inherited and 
due to germline SDHx mutations, GISTs are associated 
with PGL (35, 36), whereas they are associated with PGL 
and pulmonary chondromas in Carney triad.
Etiology of Carney triad is uncertain (37). Comparative 
genomic hybridization has shown alterations in the 1q, 
1p and less frequently in the 14 q and 22 q chromosomal 
loci (38). Although SDHB is located on chromosome 
1p36.1-p35 and SDHC on 1q21-q23.3, germline mutations 
of SDHx genes have rarely been found. Nonetheless, the 
Table 1 Clinical characteristics of the SDHx-related syndromes.
Gene Lesions Multiple lesions Penetrance Malignancy Paternaltransmission Associated neoplasms
SDHD HNPGL Yes High Very rare Yes GIST
PGL1 Thoracic PGL    PA 
Abdominal PGL    RCC
PHEO  PTC (?)
SDHB Abdominal PGL Yes (rare) Low Frequent No GIST
PGL4 HNPGL   RCC
PHEOs PA
PTC (?)
SDHC HNPGL Rare Unknown Unknown No GIST
PGL3 Abdominal PGL     RCC
     PA
SDHAF2 HNPGL Rare Unknown Unknown Yes PA 
PGL2
SDHA Abdominal PGL Rare Unknown Unknown No GIST
PGL5      PA
HNPGL, head and neck paragangliomas; PA, Pituitary adenoma; PHEO, pheochromocytomas; PGL, paragangliomas; PTC, Papillary Thyroid Carcinoma; 
RCC, Renal cell carcinoma.
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GISTs from Carney triad display loss of immunoreactivity 
for SDHB (39). This finding can be explained by SDHx 
somatic losses or by epigenetic silencing of SDHC 
promoter (40).
SDH-deficient GISTs account for 5–7.5% of all GISTs. 
Nearly all are located in the stomach, usually multiple, 
and frequently multinodular, they may metastasize to 
lymph nodes, but generally present a protracted and 
indolent course (35, 37, 41).
In summary, GISTs occur rarely in SDHx mutation 
carriers and therefore systematic screening for these tumors 
does not seem to be cost-effective. However, in the case of 
a GIST showing characteristics such as childhood onset, 
gastric location, multiple lesions, nodular/plexyform 
histology or a positive personal or family history for 
PHEO/PGL, SDHB immunostaining of the tumor or 
SDHx genetic testing on patient or tumor DNA should be 
performed. Indeed, the diagnosis of a familial form has 
important consequences on the clinical management of 
the patient and of his/her family members.
Renal cell carcinomas (RCCs)
SDHx mutated RCCs are rare tumors, estimated to account 
for 0.05–0.2% of all RCCs (42). The first report on SDHB-
mutated patients affected by both PHEO/PGL and RCCs 
was by Vanharanta et al. in 2004 (22). The renal cancers 
diagnosed in these SDHB mutation carriers appeared to 
originate from the epithelial cells of the proximal tubule 
and were composed of a mixture of clear cells and cells 
with granular-eosinophilic cytoplasm arranged in a 
variably solid or nested architecture.
In a more recent paper, Gill et  al. evaluated the 
morphology of 36 SDH-deficient RCCs from 27 patients 
and concluded that the most distinctive histologic feature 
was the presence of cytoplasmic vacuoles and inclusion-
like spaces containing either pale eosinophilic fluid or 
flocculent material (42). Nonetheless, in some cases, these 
inclusions were focal and not easy to identify. Ricketts 
et al. also reported that in 21 cases of SDH-deficient RCC, 
most tumors exhibited ‘oncocytic’ features although renal 
tumor histology was variable (43).
SDH-deficient RCC has been recognized as novel 
entity in the 2016 WHO classification of renal tumors 
(44, 45). It may show a morphologic spectrum wider than 
has been previously described (46) and some cases may be 
essentially indistinguishable from other non-SDH-related 
RCCs at histology. Of the SDH-deficient RCCs, the most 
common are those due to SDHB mutations.
According to Gill (42), SDH-deficient RCCs commonly 
present at a mean age of 37 years (range 14–76) while in 
the series of Williamson (47), the mean age is 40  years 
(range 22–72). Multifocal or bilateral tumors are detected 
in 30% of patients at long-term follow-up.
In summary, the very low prevalence of SDH-deficient 
RCCs seems to make their systematic research non-cost-
effective in SDHx mutation carriers. SDH IHC or SDHx 
genetic testing should however be considered in RCCs 
occurring in patients younger than 40 years, as multiple 
or recurrent tumors, or in the case of a positive personal or 
family history of PHEO/PGL, GISTs or RCCs.
Pituitary adenomas (PAs)
The first report of an SDH (in this case C) mutation carrier 
affected by a single HNPGL and a PA was by Lopez-Jimenez 
et al. in 2008 (48). The authors found loss of heterozygosity 
(LOH) in the HNPGL but could not verify SDH deficiency 
of the PA since the tumor tissue was not available. The 
first description of PAs related to an SDH (in this case 
D) mutation was by Xekouki et  al. in 2012 (23). They 
published the case of a 37-year-old male SDHD mutation 
carrier who presented multiple PGL in the neck, thorax 
and abdomen and a GH-secreting PA exhibiting LOH and 
downregulation of SDHD protein at immunoblotting and 
IHC. In 2013, Dwight et al. reported a case of PA arising in 
the setting of germline SDHA mutation (49).
In 2014 Gill et  al. (50) immunohistochemically 
assessed 309 PAs detecting only one SDHA-negative 
PA as the result of a double SDHA somatic mutation. 
Subsequently, Xekouki et  al. (51) performed genetic 
testing on 168 patients affected by PA, of which 146 were 
sporadic and 22 were familial.
Among the patients with sporadic PAs, 3 also displayed 
PHEO/PGL, but none of them was an SDHx mutation 
carrier. Conversely, in the group of patients with familial 
PAs, 4 also presented PHEO/PGL, 2 were SDHB and 1 
SDHD germline mutation carriers.
To the best of our knowledge, 74 patients affected by 
both PHEO/PGL and PA have been reported so far (52, 53). 
Of the 72 patients collectively analyzed by O’Toole et al. 
(52), 23 (32%) harbored no mutations but had a personal 
or family history suggestive of a hereditary endocrine 
syndrome, 28 (39%) had no mutations and no suggestive 
personal or family history and 21 (29%) were found to 
be mutated for a susceptibility gene, such as menin 
(4 patients), RET (1 patient), SDHB (6 patients), SDHD  
(5 patients), SDHC (1 patient) and SDHAF2 (1 patient). 
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The patient age at diagnosis ranged from 15 to 84 years 
with a mean of 44 years. Of the 72 patients, 34 (47.2%) 
presented a macroadenoma, 11 (15.3%) a microadenoma 
and in 27 (37.5%), the size of the PA was unavailable.
PA secretion varied but consisted mainly of GH 
(27patients, 37.5%) and PRL (23 patients 31.9%). Overall, 
13 (18.1%) patients had a non-functioning PA, 2 (2.8%) 
an ACTH-secreting tumor and 1 (1.4%) a mixed GH/PRL-
secreting adenoma. In 1 (1.4%) patient, PA was diagnosed 
as chromophobic, and in 5 (6.9%), the secretion was not 
determined.
In summary, the occurrence of PAs in SDH germline 
mutation carriers is rare, and systematic screening does 
not seem to be recommended. Conversely, SDHx genetic 
testing or SDHB IHC is advisable in the case of familial 
PAs, phenotypically aggressive and/or therapy-resistant 
PAs, early-onset PAs or patients with a positive personal or 
family history for PHEO/PGL.
Other tumors
In addition to GISTs, RCCs and PAs, other tumors have 
been reported to be associated with PHEO/PGL in SDHx 
germline mutation carriers; however, very few cases have 
been found to be related to SDH deficiency.
In 2004, Neumann et al. (16) reported the occurrence 
of papillary thyroid carcinoma (PTC) in one out of 53 
SDHB mutation carriers and in one out of 47 SDHD 
mutation carriers, although the tumor SDH dependency 
was not investigated.
The causal role of SDH in differentiated thyroid 
cancers (DTC) was evaluated by Ni et al. (54) in 754 cases. 
Germline SDHx missense variants were found in 48 (6%) 
patients, but were generally classified as non-pathogenic. 
However, papillary and follicular thyroid tumors showing 
consistent loss of SDHC/D gene expression were associated 
with earlier disease onset and higher pathologic stage. 
Although these findings identify SDHx as modifier genes 
in the clinical presentation of DTC, Papathomas et  al. 
argued against a positive link between PTC and SDH-
deficient state (55). Indeed, all the 60 cases of PTC under 
study proved immunoreactive for SDHB. Similarly, the 
authors did not find any SDHB-negative tumor among 
47 neuroblastic tumors, 50 testicular seminomas and 10 
adenomatoid adrenal tumors.
An association between SDHx mutations and 
lymphoid malignancies has been recently reported by 
Renella et al. (56) in two families. In one family, a young 
female SDHB mutation carrier was affected with abdominal 
PGL and nodular lymphocyte-predominant Hodgkin 
lymphoma staining for SDHB. The pedigree of the other 
family included a 15-year-old SDHC mutation carrier with 
metastatic GIST/PHEO and a 24-year-old maternal aunt 
diagnosed with stage IV-B Hodgkin lymphoma whose 
specimen was not available for IHC.
Finally, a pancreatic neuroendocrine tumor showing 
SDHB negativity, SDHA positivity and LOH has been 
reported in an SDHD mutation carrier who was also affected 
with oligodendroglioma and multiple HNPGL (53).
Discussion
In addition to PHEO/PGL, SDHx gene mutations are 
responsible for the occurrence of other solid tumors, 
mainly GISTs, RCCs and PAs.
The frequency of these non-neural-crest-derived 
tumors seems to be very rare, although the cases reported 
in the literature may result underestimated as no 
systematic studies aimed at diagnosing these tumors have 
been performed in SDHx mutation carriers. Nevertheless, 
SDHx mutation carriers are generally (and hopefully) 
enrolled in a lifelong screening looking for the occurrence 
of HNPGL as well as of PHEO/PGL and therefore tumors 
like RCC and PA should be diagnosed during radiological 
screening procedures, by CT or MRI, carried out on the 
abdomen or head and neck respectively.
Therefore, at present, a systematic search for 
neoplasms other than PHEO/PGL in SDHx mutation 
carriers does not seem advisable although prospective 
studies aimed at establish their frequency are necessary. 
Nevertheless, these tumors may at times present clinical 
or histologic features suggestive of SDHx dependency, 
thereby recommending SDHB IHC on tumor tissue or 
SDHx genetic testing on patient’s blood or tumor DNA. 
However, when testing tumor tissue by IHC, it must 
be recalled that SDHB IHC should be interpreted with 
caution, due to possible false positive (i.e. positive or 
weakly diffuse SDHB staining) sometimes observed in 
SDHD-mutated tumors (57). As a whole, a negative SDHB 
immunostaining proves that the tumor depends on a loss 
of SDH expression. This result should then be confirmed 
by genetic analysis on blood and/or tumor DNA to 
detect the type of mutation and whether the mutation is 
germline or somatic. When available, tumor DNA analysis 
for SDHx mutations should be performed for first. Other 
tools aimed at proving tumor SDH impairment are SDHB 
expression by western blot analysis or the measurement 
of SDH activity in tumor tissue.
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Finally, in spite of the low frequency of tumors other 
than PHEO/PGL, when screening SDHx mutation carriers 
clinicians should accurately inquire on signs or symptoms 
associated to GISTs, RCCs or PAs. Conversely, in patients 
affected by GISTs, RCCs or Pas, clinicians should collect 
an accurate personal and family history searching for 
the occurrence of PHEO/PGL. Indeed, the diagnosis of a 
genetic syndrome is clinically relevant both for the index 
case as well as for the family members.
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